Press Releases May 8, 2026 08:00 PM

electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026

electroCore to Present at LD Micro Invitational XVI Conference on May 18, 2026

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
ECOR

electroCore, Inc., a bioelectronic medicine company, announced it will participate in the LD Micro Invitational XVI Conference, with Interim President and CFO Joshua Lev delivering a presentation and holding one-on-one meetings. The event will showcase the company's innovative non-invasive bioelectronic technologies for health and wellness.

electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
ECOR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • electroCore specializes in non-invasive bioelectronic technologies for treating chronic pain and promoting wellness.
  • The company will present at a notable investor conference, indicating active investor engagement efforts.
  • electroCore markets two prescription products: gammaCore (vagus nerve stimulation) and Quell neurostimulator, plus handheld wellness devices Truvaga and TAC-STIM.
  • Sectors impacted include healthcare technology, medical devices, and wellness markets.

ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, CA.   Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day.  

LD Micro Invitational XVI Conference Details:

Date: Monday, May 18, 2026

Company Presentation: 10:30 am PT

Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA

Webcast:   Click for Link

For more information or to attend the conference, click here.

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
[email protected] 


Risks

  • Market acceptance of bioelectronic devices could be uncertain, impacting sales and growth.
  • Competition within the medical device and bioelectronic wellness space may pressure market share.
  • Regulatory risks around medical device approvals and compliance could affect product commercialization.

More from Press Releases

Lake City Bank Announces Significant Market Expansion in Fort Wayne at Electric Works Oct 7, 2026 Real Messenger Announces It has Regained Compliance with Nasdaq Stockholders’ Equity Requirement Oct 7, 2026 Algorhythm Introduces Azure P2P™, a Renewable Power Generation Process Designed to Deliver Around-the-Clock Power Oct 7, 2026 Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform Oct 7, 2026 Circle8 Netherlands Secures $314 Million Four-Year Contract With DUO Groningen Oct 7, 2026